

DiagnosTear Ltd. - Recruitment of the first participant for clinical trial using the TeaRx™ technology

The Company hereby announces that on August 31, 2017, DiagnosTear Ltd. ("DiagnosTear") announced the recruitment of a first participant for an additional clinical trial to examine a product based on the TeaRx™ technology, which is used to diagnose, personalize treatment and monitoring Dry eye syndrome by examining the composition of the tear film. This trial is carried out as part of the regulatory approval processes of the point of care product (the "Trial" and "the Product", respectively).

The main objective of the trial is to ensure the repeatability of the positive findings observed in the two previous clinical trials in the identification of dry eye patients from a population containing healthy and dry eye patients and for the purpose of expanding the clinical database prior to submitting the product for obtaining marketing approvals from the regulatory authorities in Europe

The trial will be conducted in the United States at two different medical centers and is expected to include approximately 82 participants. According to Diagnostic the trial is expected to be completed during the fourth quarter of 2017.

